Biotech manufacturing advanced nanoparticle sensors to monitor diseases
Glympse Bio is an MIT spin-out from the laboratory of renowned bioengineer, Dr. Sangeeta Bhatia. Glympse Bio is headquartered in Cambridge, MA.
Glympse Bio develops modular nanoparticle sensors to create diagnostics for diseases. It uses engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis.
Visit website: https://glympsebio.com/
Mentioned in this Resource
Private land-grant research university
Biomedical researcher and John J. and Dorothy Wilson Professor at MIT
Glympse Bio News
New urine test detects cancer cells and their location using nanoparticles
Massachusetts Institute of Technology (MIT) - 15-Jul-2021
Screening cancers non-invasively; shows safety in phase 1 trialsRead more...